help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on April 7, 2006, doi:10.1164/rccm.200512-1922OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200512-1922OCv1
174/1/84    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Christ-Crain, M.
Right arrow Articles by Müller, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Christ-Crain, M.
Right arrow Articles by Müller, B.
American Journal of Respiratory and Critical Care Medicine Vol 174. pp. 84-93, (2006)
© 2006 American Thoracic Society
doi: 10.1164/rccm.200512-1922OC

Original Article

Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia

A Randomized Trial

Mirjam Christ-Crain, Daiana Stolz, Roland Bingisser, Christian Müller, David Miedinger, Peter R. Huber, Werner Zimmerli, Stephan Harbarth, Michael Tamm and Beat Müller

Departments of Internal Medicine, Endocrinology, Pneumology, Emergency Medicine, and Clinical Chemistry, University Hospital, Basel; Medical University Clinic, Kantonsspital, Liestal; and Division of Hospital Epidemiology, University Hospital, Geneva, Switzerland

Correspondence and requests for reprints should be addressed to Mirjam Christ-Crain, M.D., University Hospital, Petersgraben 4, CH-4031 Basel, Switzerland. E-mail: christmj{at}bluewin.ch

Rationale: In patients with community-acquired pneumonia, guidelines recommend antibiotic treatment for 7 to 21 d. Procalcitonin is elevated in bacterial infections, and its dynamics have prognostic implications.

Objective: To assess procalcitonin guidance for the initiation and duration of antibiotic therapy in community-acquired pneumonia.

Methods: In a randomized intervention trial, 302 consecutive patients with suspected community-acquired pneumonia were included. Data were assessed at baseline, after 4, 6, and 8 d, and after 6 wk.

The control group (n = 151) received antibiotics according to usual practice. In the procalcitonin group (n = 151), antibiotic treatment was based on serum procalcitonin concentrations as follows: strongly discouraged, less than 0.1 µg/L; discouraged, less than 0.25 µg/L; encouraged, greater than 0.25 µg/L; strongly encouraged, greater than 0.5 µg/L. The primary endpoint was antibiotic use; secondary endpoints were measures of clinical, laboratory, and radiographic outcome.

Results: At baseline, both groups were similar regarding clinical, laboratory, and microbiology characteristics, and Pneumonia Severity Index. Procalcitonin guidance reduced total antibiotic exposure (relative risk, 0.52; 95% confidence interval, 0.48–0.55; p < 0.001), antibiotic prescriptions on admission (85 vs. 99%; p < 0.001), and antibiotic treatment duration (median, 5 vs. 12 d; p < 0.001) compared with patients treated according to guidelines. After adjustment for Pneumonia Severity Index, the hazard ratio of antibiotic discontinuation was higher in the procalcitonin group than in the control group (3.2; 95% confidence interval, 2.5 to 4.2). Outcome was similar in both groups, with an overall success rate of 83%.

Conclusions: Procalcitonin guidance substantially reduces antibiotic use in community-acquired pneumonia. These findings may have important clinical and public health implications.

Key Words: antibiotic therapy • community-acquired pneumonia • procalcitonin




This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
J. D. Chalmers, M. Al-Khairalla, P. M. Short, T. C. Fardon, and J. H. Winter
Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic
J. Antimicrob. Chemother., April 1, 2010; 65(4): 608 - 618.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
P. Schuetz, W. Zimmerli, and B. Mueller
Procalcitonin-Based Guidelines and Lower Respiratory Tract Infections--Reply
JAMA, February 3, 2010; 303(5): 419 - 420.
[Full Text] [PDF]

Home page
 JAMAHome page
C. Stijnis, C. van Nieuwkoop, and J. T. van Dissel
Procalcitonin-Based Guidelines and Lower Respiratory Tract Infections
JAMA, February 3, 2010; 303(5): 418 - 419.
[Full Text] [PDF]

Home page
 JBJSHome page
S. Hunziker, T. Hugle, K. Schuchardt, I. Groeschl, P. Schuetz, B. Mueller, W. Dick, U. Eriksson, and A. Trampuz
The Value of Serum Procalcitonin Level for Differentiation of Infectious from Noninfectious Causes of Fever After Orthopaedic Surgery
J. Bone Joint Surg. Am., January 1, 2010; 92(1): 138 - 148.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
D. Stolz, N. Smyrnios, P. Eggimann, H. Pargger, N. Thakkar, M. Siegemund, S. Marsch, A. Azzola, J. Rakic, B. Mueller, et al.
Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study
Eur. Respir. J., December 1, 2009; 34(6): 1364 - 1375.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
R Menendez, R Martinez, S Reyes, J Mensa, E Polverino, X Filella, C Esquinas, A Martinez, P Ramirez, and A Torres
Stability in community-acquired pneumonia: one step forward with markers?
Thorax, November 1, 2009; 64(11): 987 - 992.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
P. Schuetz, M. Christ-Crain, R. Thomann, C. Falconnier, M. Wolbers, I. Widmer, S. Neidert, T. Fricker, C. Blum, U. Schild, et al.
Effect of Procalcitonin-Based Guidelines vs Standard Guidelines on Antibiotic Use in Lower Respiratory Tract Infections: The ProHOSP Randomized Controlled Trial
JAMA, September 9, 2009; 302(10): 1059 - 1066.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. M. Yealy and M. J. Fine
Measurement of Serum Procalcitonin: A Step Closer to Tailored Care for Respiratory Infections?
JAMA, September 9, 2009; 302(10): 1115 - 1116.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. Struck, M. Strebelow, S. Tietz, C. Alonso, N. G. Morgenthaler, J. G. van der Hoeven, P. Pickkers, and A. Bergmann
Method for the Selective Measurement of Amino-Terminal Variants of Procalcitonin
Clin. Chem., September 1, 2009; 55(9): 1672 - 1679.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. Mertz, M. Koller, P. Haller, M. L. Lampert, H. Plagge, B. Hug, G. Koch, M. Battegay, U. Fluckiger, and S. Bassetti
Outcomes of early switching from intravenous to oral antibiotics on medical wards
J. Antimicrob. Chemother., July 1, 2009; 64(1): 188 - 199.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
J. S Brown
Biomarkers and community-acquired pneumonia
Thorax, July 1, 2009; 64(7): 556 - 558.
[Full Text] [PDF]

Home page
 ChestHome page
M.-C. Lin, Y.-C. Chen, J.-T. Wu, Y.-C. Ko, and C.-C. Wang
Diagnostic and Prognostic Values of Pleural Fluid Procalcitonin in Parapneumonic Pleural Effusions
Chest, July 1, 2009; 136(1): 205 - 211.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
A. Lacoma, C. Prat, F. Andreo, and J. Dominguez
Biomarkers in the management of COPD
Eur. Respir. Rev., June 1, 2009; 18(112): 96 - 104.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
A. Singanayagam, J.D. Chalmers, and A.T. Hill
Severity assessment in community-acquired pneumonia: a review
QJM, June 1, 2009; 102(6): 379 - 388.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
K. L. Lawrence and M. H. Kollef
Antimicrobial Stewardship in the Intensive Care Unit: Advances and Obstacles
Am. J. Respir. Crit. Care Med., March 15, 2009; 179(6): 434 - 438.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
M. Briel, P. Schuetz, B. Mueller, J. Young, U. Schild, C. Nusbaumer, P. Periat, H. C. Bucher, and M. Christ-Crain
Procalcitonin-Guided Antibiotic Use vs a Standard Approach for Acute Respiratory Tract Infections in Primary Care
Arch Intern Med, October 13, 2008; 168(18): 2000 - 2007.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
D. N. Schwartz
Procalcitonin-Guided Antibiotic Use vs a Standard Approach for Acute Respiratory Tract Infections in Primary Care
Arch Intern Med, October 13, 2008; 168(18): 2007 - 2008.
[Full Text] [PDF]

Home page
 Chronic Respiratory DiseaseHome page
M. Loebinger, A Shoemark, M Berry, M Kemp, and R Wilson
Procalcitonin in stable and unstable patients with bronchiectasis
Chronic Respiratory Disease, August 1, 2008; 5(3): 155 - 160.
[Abstract] [PDF]

Home page
 ThoraxHome page
S. Ewig and T. Welte
CRB-65 for the assessment of pneumonia severity: who could ask for more?
Thorax, August 1, 2008; 63(8): 665 - 666.
[Full Text] [PDF]

Home page
 ThoraxHome page
R Menendez, M Cavalcanti, S Reyes, J Mensa, R Martinez, M A Marcos, X Filella, M Niederman, and A Torres
Markers of treatment failure in hospitalised community acquired pneumonia
Thorax, May 1, 2008; 63(5): 447 - 452.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
W. MacNee
Update in Chronic Obstructive Pulmonary Disease 2007
Am. J. Respir. Crit. Care Med., April 15, 2008; 177(8): 820 - 829.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
V. Nobre, S. Harbarth, J.-D. Graf, P. Rohner, and J. Pugin
Use of Procalcitonin to Shorten Antibiotic Treatment Duration in Septic Patients: A Randomized Trial
Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 498 - 505.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Kruger, S. Ewig, R. Marre, J. Papassotiriou, K. Richter, H. von Baum, N. Suttorp, T. Welte, and on behalf of the CAPNETZ Study Group
Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes
Eur. Respir. J., February 1, 2008; 31(2): 349 - 355.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
F. J. Martinez
Pathogen-directed Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, December 1, 2007; 4(8): 647 - 658.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Masia, J. Papassotiriou, N. G. Morgenthaler, I. Hernandez, C. Shum, and F. Gutierrez
Midregional Pro-A-Type Natriuretic Peptide and Carboxy-Terminal Provasopressin May Predict Prognosis in Community-Acquired Pneumonia
Clin. Chem., December 1, 2007; 53(12): 2193 - 2201.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Christ-Crain, D. Stolz, S. Jutla, O. Couppis, C. Muller, R. Bingisser, P. Schuetz, M. Tamm, R. Edwards, B. Muller, et al.
Free and Total Cortisol Levels as Predictors of Severity and Outcome in Community-acquired Pneumonia
Am. J. Respir. Crit. Care Med., November 1, 2007; 176(9): 913 - 920.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Christ-Crain and B. Muller
Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators
Eur. Respir. J., September 1, 2007; 30(3): 556 - 573.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. Stolz, A. Stulz, B. Muller, A. Gratwohl, and M. Tamm
BAL Neutrophils, Serum Procalcitonin, and C-Reactive Protein To Predict Bacterial Infection in the Immunocompromised Host
Chest, August 1, 2007; 132(2): 504 - 514.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. W. Arnold, J. T. Summersgill, A. S. LaJoie, P. Peyrani, T. J. Marrie, P. Rossi, F. Blasi, P. Fernandez, T. M. File Jr., J. Rello, et al.
A Worldwide Perspective of Atypical Pathogens in Community-acquired Pneumonia
Am. J. Respir. Crit. Care Med., May 15, 2007; 175(10): 1086 - 1093.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
E. B. Milbrandt, A. Ishizaka, and D. C. Angus
Update in Critical Care 2006
Am. J. Respir. Crit. Care Med., April 1, 2007; 175(7): 638 - 648.
[Full Text] [PDF]

Home page
 ChestHome page
D. Stolz, M. Christ-Crain, N. G. Morgenthaler, J. Leuppi, D. Miedinger, R. Bingisser, C. Muller, J. Struck, B. Muller, and M. Tamm
Copeptin, C-Reactive Protein, and Procalcitonin as Prognostic Biomarkers in Acute Exacerbation of COPD
Chest, April 1, 2007; 131(4): 1058 - 1067.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. S. Niederman
Recent Advances in Community-Acquired Pneumonia: Inpatient and Outpatient
Chest, April 1, 2007; 131(4): 1205 - 1215.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. J. Martinez and J. L. Curtis
Procalcitonin-Guided Antibiotic Therapy in COPD Exacerbations: Closer But Not Quite There
Chest, January 1, 2007; 131(1): 1 - 2.
[Full Text] [PDF]

Home page
 ChestHome page
D. Stolz, M. Christ-Crain, R. Bingisser, J. Leuppi, D. Miedinger, C. Muller, P. Huber, B. Muller, and M. Tamm
Antibiotic Treatment of Exacerbations of COPD: A Randomized, Controlled Trial Comparing Procalcitonin-Guidance With Standard Therapy
Chest, January 1, 2007; 131(1): 9 - 19.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Med.Home page
Other articles noted
Evid. Based Med., December 1, 2006; 11(6): 191 - 192.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. P. Espana, A. Capelastegui, I. Gorordo, C. Esteban, M. Oribe, M. Ortega, A. Bilbao, and J. M. Quintana
Development and Validation of a Clinical Prediction Rule for Severe Community-acquired Pneumonia
Am. J. Respir. Crit. Care Med., December 1, 2006; 174(11): 1249 - 1256.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
B. Muller and M. Tamm
Biomarkers in acute exacerbation of chronic obstructive pulmonary disease: among the blind, the one-eyed is king.
Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 848 - 849.
[Full Text] [PDF]

Home page
 JWatch Infect. DiseasesHome page
CAP: Guiding Therapy with Procalcitonin Levels?
Journal Watch Infectious Diseases, July 12, 2006; 2006(712): 6 - 6.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. G. Wunderink
A CAP on Antibiotic Duration.
Am. J. Respir. Crit. Care Med., July 1, 2006; 174(1): 3 - 5.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2006 American Thoracic Society 		  Registrer for the conference